FyoniBio to Develop Production Cell Line for Strike Pharma’s Novel Bi-Specific Antibody
FyoniBio and Strike Pharma have signed a Master Service Agreement to advance the cell line development for Strike’s innovative therapeutic mAb candidate. Using its flexible CHOnamite® platform, FyoniBio will screen multiple host cell lines to identify the optimal production system tailored to Strike Pharma’s novel bi-specific antibody format.
